{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:26:47Z","timestamp":1778660807036,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001219","name":"The Lymphoma Research Foundation","doi-asserted-by":"crossref","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mary Aileen Wright and Frederick Kullman Memorial"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.bbmt.2014.02.004","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T03:15:48Z","timestamp":1392174948000},"page":"770-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age \u2265 60\u00a0Years with B Cell Lymphoma"],"prefix":"10.1016","volume":"20","author":[{"given":"Ajay K.","family":"Gopal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted A.","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph G.","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell R.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-4869","authenticated-orcid":false,"given":"Andrew","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.02.004_bib1","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bbmt.2014.02.004_bib2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.bmt.1702833","article-title":"Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older","volume":"27","author":"Gopal","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.004_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1705266","article-title":"Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis","volume":"37","author":"Jantunen","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.004_bib4","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3324\/haematol.13273","article-title":"Autologous stem cell transplantation in elderly patients (> or\u00a0=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry","volume":"93","author":"Jantunen","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.02.004_bib5","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.02.004_bib6","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A\u00a0phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib7","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib8","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A\u00a0phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","article-title":"High-dose [131I] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or\u00a0= 60 years old with relapsed or refractory B-cell lymphoma","volume":"25","author":"Gopal","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.02.004_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1097-0215(20000101)85:1<104::AID-IJC19>3.0.CO;2-G","article-title":"Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas","volume":"85","author":"Johnson","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bbmt.2014.02.004_bib11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbmt.2006.03.014","article-title":"Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy","volume":"12","author":"Gopal","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.004_bib12","first-page":"3981","article-title":"Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2'-deoxycoformycin and deoxyadenosine in\u00a0vitro","volume":"48","author":"Begleiter","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2014.02.004_bib13","first-page":"1257","article-title":"Imaging and treatment of B-cell lymphoma","volume":"31","author":"Eary","year":"1990","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.bbmt.2014.02.004_bib14","first-page":"1059","article-title":"High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes","volume":"45","author":"Rajendran","year":"2004","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.bbmt.2014.02.004_bib15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.02.004_bib16","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.02.004_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2014.02.004_bib18","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.02.004_bib19","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2010-02-270538","article-title":"Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study","volume":"116","author":"Bethge","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib20","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2010-12-324392","article-title":"(9)(0)Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma","volume":"118","author":"Gopal","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib21","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","article-title":"Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011","volume":"20","author":"Morrison","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.02.004_bib22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/bmt.2011.109","article-title":"Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation","volume":"47","author":"Waterman","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.004_bib23","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.V95.5.1588.005k38_1588_1593","article-title":"Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors","volume":"95","author":"Krishnan","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib24","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.02.004_bib25","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.bbmt.2013.08.005","article-title":"Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European Group for Blood and Marrow Transplantation","volume":"19","author":"Lanza","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.004_bib26","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1182\/blood-2009-02-205476","article-title":"131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma","volume":"113","author":"Gopal","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib27","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2008-01-132142","article-title":"Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab","volume":"112","author":"Gopal","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib28","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib30","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.02.004_bib31","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bbmt.2014.02.004_bib32","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.bmt.1705371","article-title":"Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma","volume":"37","author":"Buadi","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.004_bib33","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.bbmt.2008.05.002","article-title":"Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma","volume":"14","author":"Wildes","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.02.004_bib34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ajh.23108","article-title":"Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity","volume":"87","author":"Elstrom","year":"2012","journal-title":"Am J Hematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114000810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114000810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:47:23Z","timestamp":1761058043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114000810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1083879114000810"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.02.004","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age \u2265 60\u00a0Years with B Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}